Crinetics Pharmaceuticals (CRNX) Competitors $28.87 -2.52 (-8.03%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$27.76 -1.11 (-3.84%) As of 08:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRNX vs. MRNA, GMAB, RDY, VTRS, ASND, PCVX, QGEN, ROIV, SRPT, and RVMDShould you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Moderna (MRNA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Ascendis Pharma A/S (ASND), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), Sarepta Therapeutics (SRPT), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Crinetics Pharmaceuticals vs. Moderna Genmab A/S Dr. Reddy's Laboratories Viatris Ascendis Pharma A/S Vaxcyte Qiagen Roivant Sciences Sarepta Therapeutics Revolution Medicines Moderna (NASDAQ:MRNA) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, earnings, profitability, dividends, valuation, institutional ownership and media sentiment. Is MRNA or CRNX more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -110.04%. Moderna's return on equity of -28.74% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Moderna-110.04% -28.74% -21.83% Crinetics Pharmaceuticals N/A -36.12%-31.89% Which has more risk & volatility, MRNA or CRNX? Moderna has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Do insiders and institutionals hold more shares of MRNA or CRNX? 75.3% of Moderna shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 11.0% of Moderna shares are held by insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer MRNA or CRNX? Moderna presently has a consensus price target of $59.00, indicating a potential upside of 129.30%. Crinetics Pharmaceuticals has a consensus price target of $73.00, indicating a potential upside of 152.86%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04Crinetics Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92 Which has stronger valuation & earnings, MRNA or CRNX? Crinetics Pharmaceuticals has lower revenue, but higher earnings than Moderna. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.20B3.11-$3.56B-$9.28-2.77Crinetics Pharmaceuticals$1.04M2,585.49-$214.53M-$3.71-7.78 Does the MarketBeat Community believe in MRNA or CRNX? Moderna received 56 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 69.43% of users gave Crinetics Pharmaceuticals an outperform vote while only 53.88% of users gave Moderna an outperform vote. CompanyUnderperformOutperformModernaOutperform Votes21553.88% Underperform Votes18446.12% Crinetics PharmaceuticalsOutperform Votes15969.43% Underperform Votes7030.57% Does the media favor MRNA or CRNX? In the previous week, Moderna had 31 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 41 mentions for Moderna and 10 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.41 beat Moderna's score of 0.55 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 19 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 10 Negative mention(s) 1 Very Negative mention(s) Positive Crinetics Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive SummaryCrinetics Pharmaceuticals beats Moderna on 10 of the 19 factors compared between the two stocks. Remove Ads Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRNX vs. The Competition Export to ExcelMetricCrinetics PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.92B$6.72B$5.53B$7.50BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-7.746.9923.1218.08Price / Sales2,585.49198.60360.0289.38Price / CashN/A65.6738.1634.64Price / Book3.585.926.473.99Net Income-$214.53M$142.37M$3.21B$247.18M7 Day Performance-16.87%-7.24%-4.97%-4.25%1 Month Performance-15.24%-10.45%-0.14%-6.87%1 Year Performance-38.11%-14.58%6.19%-3.73% Crinetics Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRNXCrinetics Pharmaceuticals4.345 of 5 stars$28.87-8.0%$73.00+152.9%-39.4%$2.92B$1.04M-7.74210News CoveragePositive NewsGap DownMRNAModerna4.2855 of 5 stars$34.17+4.6%$59.00+72.7%-74.6%$13.18B$3.20B-3.683,900Gap DownGMABGenmab A/S3.8134 of 5 stars$19.29-2.4%$41.33+114.3%-34.3%$12.77B$21.53B11.092,204Analyst DowngradeRDYDr. Reddy's Laboratories3.3199 of 5 stars$13.72+0.0%$17.00+24.0%-9.5%$11.45B$311.31B21.8424,800Positive NewsHigh Trading VolumeVTRSViatris2.6159 of 5 stars$9.30+1.6%$10.50+12.9%-32.1%$11.10B$14.74B-12.5737,000ASNDAscendis Pharma A/S3.0183 of 5 stars$167.99+1.2%$204.64+21.8%+0.4%$10.20B$363.64M-23.661,017Positive NewsGap DownPCVXVaxcyte2.5784 of 5 stars$73.82-1.1%$147.50+99.8%-53.1%$9.51BN/A-16.05160Analyst ForecastAnalyst RevisionNews CoverageGap DownQGENQiagen3.4911 of 5 stars$39.87+0.5%$47.71+19.7%-0.9%$8.85B$1.98B111.026,030Gap UpROIVRoivant Sciences2.3564 of 5 stars$10.83+0.4%$18.08+67.0%-13.0%$7.73B$122.59M-72.20860SRPTSarepta Therapeutics4.7905 of 5 stars$76.33+3.0%$167.41+119.3%-53.8%$7.41B$1.90B61.061,314Quiet Period ExpirationNews CoverageGap UpRVMDRevolution Medicines4.12 of 5 stars$39.34+3.2%$66.31+68.6%+4.7%$7.31B$742,000.00-10.96250Analyst ForecastNews CoveragePositive NewsGap Down Remove Ads Related Companies and Tools Related Companies Moderna Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Viatris Competitors Ascendis Pharma A/S Competitors Vaxcyte Competitors Qiagen Competitors Roivant Sciences Competitors Sarepta Therapeutics Competitors Revolution Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRNX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
